First Tracks Biotherapeutics, Inc.

TRAX Nasdaq SEC CIK 2091349
Follow First Tracks Biotherapeutics Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Net income −$31.4M +25.1% vs same quarter last year
EPS, diluted −$0.88 +41.3% vs same quarter last year
Operating cash flow −$17.1M +44.4% vs same quarter last year
Operating income −$32.8M +27.1% vs same quarter last year
Net income by quarter
−$47.2M
−$42.4M
−$41.9M
−$34.6M
−$50.5M
−$33.4M
−$31.4M
Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing